# FDA approves Zevaskyn, the first cell-based gene therapy for wounds of recessive dystrophic epidermolysis bullosa

Canonical page: https://technooptimist.io/stories/fda-approves-zevaskyn-the-first-cell-based-gene-therapy-for-wounds-of-5800a692
Date: 29 Apr 2025
About: [Abeona Therapeutics](https://technooptimist.io/companies/abeona-therapeutics.md) · [Zevaskyn (pz-cel)](https://technooptimist.io/biotech/zevaskyn.md)
Original source: https://www.europeanpharmaceuticalreview.com/news/254869/fda-approves-first-of-a-kind-gene-therapy-for-dystrophic-epidermolysis-bullosa

The FDA approved Zevaskyn (prademagene zamikeracel) for wounds in adults and children with recessive dystrophic epidermolysis bullosa, a genetic disease where skin tears and blisters at the slightest friction. The patient's own skin cells are modified to make working type VII collagen and grafted as sheets onto chronic wounds in a single procedure. In the VIITAL phase 3, most treated wounds healed at least halfway by six months.

## Key facts

- VIITAL: 81% of large chronic wounds reached ≥50% healing at 6 months vs 16% of 43 matched control wounds.
- No treatment-related serious adverse events reported across both clinical studies.
- Approved for adults and children from birth; applied once per wound area.

---

The Techno Optimist tracks every frontier of technology, program by program: https://technooptimist.io/ (a Markdown version of any page: add .md to its URL; site map for agents: https://technooptimist.io/llms.txt).
Data API (JSON, realtime stream): https://technooptimist.io/developers. People read 5 pages free, then Reader $10/month; these Markdown pages are open to agents.